Enovis Corporation — Q1 2024 Form 10-Q Summary
Reporting period: Three months ended March 29, 2024, compared with the three months ended March 31, 2023. Enovis is a medical technology company operating through Prevention & Recovery (P&R) and Reconstructive (Recon). The quarter includes LimaCorporate S.p.A. (“Lima”) from its January 3, 2024 acquisition date.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Net sales | $516.3 million | $406.2 million | 27.1% increase |
| Gross profit | $297.9 million | $235.1 million | 26.7% increase |
| Gross margin | 57.7% | 57.9% | 20 basis-point decline |
| Operating loss | $(35.0) million | $(25.0) million | Loss increased |
| Net loss from continuing operations | $(71.8) million | $(22.8) million | Loss increased |
| Net loss attributable to Enovis | $(72.0) million | $(23.4) million | Loss increased |
| Diluted loss per share | $(1.32) | $(0.42) | $(0.90) decrease |
| Adjusted EBITDA | $83.2 million | $56.4 million | 47.7% increase |
| Adjusted EBITDA margin | 16.1% | 13.9% | 220 basis-point increase |
| Operating cash flow | $(36.2) million | $7.5 million | $43.6 million unfavorable |
Sales growth was primarily acquisition-driven. P&R sales increased 3.3% to $259.0 million, while Recon sales increased 65.5% to $257.3 million. Recon pro forma sales growth was approximately 7.0%, reflecting volume and market-share gains partly offset by integration-related impacts.
Cash flow, liquidity and debt
- Cash, cash equivalents and restricted cash totaled $74.5 million at March 29, 2024, compared with $44.8 million at December 31, 2023.
- Operating activities used $36.2 million, reflecting working-capital investment, strategic transaction costs and higher interest payments.
- Investing activities used $797.8 million, including $760.7 million paid for Lima, net of acquired cash, and $36.9 million for property, plant and equipment and intangible assets.
- Financing activities provided $864.5 million, primarily from $400.0 million of term-loan borrowings and $480.0 million of revolving-credit borrowings.
- Total debt was $1.34 billion at March 29, 2024, compared with $466.2 million at December 31, 2023. Debt included a $391.4 million term loan, $446.9 million of senior unsecured convertible notes and $500.2 million of revolving-credit and other borrowings.
- The Revolver had $400 million available at quarter-end. The weighted-average interest rate on borrowings under the credit agreement was 6.06%.
- Debt agreements include a maximum senior secured leverage ratio of 3.75:1.00, stepping down to 3.50:1.00 for the quarter ending June 30, 2024 and thereafter, and a minimum interest-coverage ratio of 3.00:1.00. The company reported compliance with these covenants.
- Letters of credit and surety bonds outstanding totaled $32.8 million. Management stated that liquidity was adequate to fund operations for the next twelve months.
Material changes and unusual items
- Lima acquisition: Completed January 3, 2024, for total fair value consideration of $868.5 million, including $760.7 million of cash paid, net of acquired cash, and contingent issuance of 1,942,686 Enovis shares. Lima contributed $85.8 million of sales and $3.6 million of net income during the quarter.
- The acquisition added approximately $385.3 million of goodwill and $341.0 million of intangible assets on a provisional basis. Purchase-accounting estimates remain subject to adjustment, which could be material.
- Strategic transaction costs increased to $20.8 million from $11.6 million, including Lima-related advisory and integration costs. Lima-related professional fees included in SG&A were $9.7 million.
- Restructuring and other charges increased to $12.9 million from $2.9 million. The company recorded $7.6 million of restructuring provisions, with a $5.6 million accrued restructuring liability at quarter-end.
- Other expense included a $13.4 million mark-to-market loss on the contingent Lima share liability and an $11.1 million loss on non-designated currency forwards used for the Lima purchase price.
- Interest expense increased to $20.0 million from $5.7 million because of acquisition-related debt financing.
- Gross margin was pressured by $5.0 million of inventory fair-value step-up amortization related to Lima and by product mix in Recon.
- Foreign currency translation produced a $65.5 million loss in other comprehensive income, partly offset by $24.8 million of hedging gains. Approximately 43% of sales were generated outside the United States.
Outlook, risks and management commentary
The filing does not provide a specific quantitative revenue, earnings or cash-flow outlook. Management expects ongoing cash requirements for working capital, acquisitions, capital expenditures, restructuring, interest and debt repayments, and believes available liquidity is adequate for the next twelve months.
- Management’s strategy continues to emphasize strategic acquisitions, integration through the Enovis Growth Excellence system, organic growth, operating improvement and margin expansion.
- Key risks include Lima integration and realization of expected synergies, elevated leverage and variable interest rates, foreign-exchange volatility, supply and commodity costs, manufacturing disruptions, regulatory approvals and compliance, product liability and recalls, reimbursement pressure, cybersecurity, intellectual property, competition and potential impairment of goodwill or intangible assets.
- A hypothetical 1% increase in interest rates would have increased quarterly interest expense on variable-rate debt by approximately $2.1 million.
- Pending legal and regulatory matters arise in the ordinary course. Management does not expect them to have a material adverse effect, although adverse outcomes could be material.
- Management stated that disclosure controls were effective. Lima’s internal controls are being incorporated into Enovis’s control framework; the company expects to complete its assessment within the applicable SEC period.
Important facts for investors to verify
- Whether Lima integration delivers the stated pro forma growth, synergies and anticipated margin expansion.
- The company’s ability to reduce leverage while funding acquisitions and operating with negative operating cash flow.
- Compliance with the credit agreement’s leverage and interest-coverage covenants after the June 30, 2024 leverage-ratio step-down.
- The final purchase-accounting values for Lima, including goodwill, intangible assets, inventory step-up and deferred taxes.
- The timing and ultimate fair value or issuance of the 1,942,686 contingent Lima acquisition shares.
- The sustainability of the 16.1% Adjusted EBITDA margin and the extent to which it depends on non-GAAP adjustments.
- Exposure to foreign-currency movements, including the $450 million Swiss franc cross-currency hedge and the company’s broader international operations.
- Progress on restructuring, regulatory compliance, product approvals, reimbursement conditions and pending legal matters.